Board of Directors

MARK P. CARTHY - General Partner, Oxford Bioscience Partners. Chairman. Mr. Carthy has been Chairman of the Board of Directors of Cyberkinetics since August 2002. Mr. Carthy joined Oxford Bioscience Partners in October of 2000. He has more than 20 years of experience operating or investing in high technology companies. He is responsible for investments in Salix Pharmaceuticals, ImpactRx, Astex Therapeutics, Solexa, Cyberkinetics, Xanthus, PowderMed, Trubion, Cardiome and Ensemble. Prior to joining Oxford, he was Biotechnology Portfolio Manager at the venture capital firm of Morningside Ventures where he focused on early stage private equity investments. Previously, he was Chief Business Officer of Cubist Pharmaceuticals, Inc. and Senior Director of Business Development at Vertex Pharmaceuticals Incorporated. He received his B.E. in chemical engineering from University College Dublin, Ireland, an M.S. in chemical engineering from University of Missouri and an M.B.A. from Harvard Business School.

DANIEL E. GEFFKEN - Executive Vice President and Chief Financial Officer, Konarka Technologies, Inc. Mr. Geffken has been a director of Cyberkinetics since January 2005 and is currently the Executive Vice President and Chief Financial Officer of Konarka Technologies, Inc. Mr. Geffken joined Konarka Technologies, Inc. in August of 2006. Previously, Mr. Geffken was Senior Vice President and Chief Financial Officer of Omnisonics Medical Technologies, Inc., from December 2003 until August 2006. He was Senior Vice President of Finance and Chief Financial Officer at Transkaryotic Therapies, Inc., from February 1997 to April 2003. Prior to Transkaryotic Therapies, Inc., Mr. Geffken held a variety of senior financial roles at CytoTherapeutics, Inc., Anderson Group (now Moscow CableCom Corp.) and Medchem Products (now C. R. Bard Inc.). Mr. Geffken also spent several years at KPMG. He received his Bachelor of Science Degree in Economics from The Wharton School at the University of Pennsylvania in 1979 and his Master’s Degree in Business Administration from the Harvard University Graduate School of Business Administration in 1987.

GEORGE N. HATSOPOULOS, Ph.D. - Founder, Chairman and Chief Executive Officer, Pharos. Dr. Hatsopoulos is the founder of Thermo Electron Corporation, a world leader in analytical and monitoring instruments. He served as Chairman and Chief Executive Officer from its founding in 1956 until his retirement in 1999. During his tenure, Thermo Electron grew into an international company with over 24,000 employees in 23 countries, and created 23 publicly traded corporations addressing diverse markets varying from heart assist devices to biomass electric generation. Dr. Hatsopoulos was trained at the National Technical University of Athens and MIT, where he received his Bachelors degree in 1949, his Masters degree in 1950, his Engineers degree in 1954, and his Doctorate degree in 1956. He was on the faculty of MIT from 1956 - 1962 and a Senior Lecturer until 1990.

NICHOLAS G. HATSOPOULOS, Ph.D. - Assistant Professor, University of Chicago. A founder of Cyberkinetics, Dr. Hatsopoulos has been an Assistant Professor in Organismal Biology and Anatomy at the University of Chicago since 2002. From 1998-2001, Dr. Hatsopoulos was an Assistant Professor of Research in the Department of Neuroscience at Brown University. Dr. Hatsopoulos has completed two postdoctoral research fellows, one in the Department of Neuroscience at Brown University and the other in the Computation Neuroscience Program at the California Institute of Technology. Currently his research focuses on the neural basis of motor control and learning and he is investigating what features of motor behavior are encoded and how this information is represented in the collective activity of neuronal ensembles in the motor cortex. Dr. Hatsopoulos completed his B.A. in Physics from Williams College in 1984, his M.S. in Psychology in 1991 and his Ph.D. in Cognitive Science from Brown University in 1992.

THEO MELAS-KYRIAZI. Mr. Melas-Kyriazi has been a director of Cyberkinetics since November 2004. He is currently self-employed. Mr. Melas-Kyriazi was affiliated with Thermo Electron Corporation from 1986 to October 2004. He served as Chief Financial Officer of TMO from 1999 until October 2004, and from 1994 to 1997, he served as Chief Executive Officer and President of Thermo Spectra Corporation, a publicly traded subsidiary of TMO. Mr. Melas-Kyriazi has also served as a member of the Board of Directors of Valeant Pharmaceuticals since 2003. Mr. Melas-Kyriazi received his Bachelor of Arts Degree in Economics from Harvard College in 1981 and his MBA from The Harvard Business School in 1983.

TIMOTHY R. SURGENOR - President, Chief Executive Officer and Director.

JOHN P. DONOGHUE, Ph.D. - Founder, Chief Scientific Officer and Director.

MARK A. CARNEY - Executive Vice President and Director.

Audit Committee: Theo Melas-Kyriazi, Daniel E. Geffken and Mark P. Carthy

Compensation Committee: Theo Melas-Kyriazi, Mark P. Carthy and Philip W. Morgan

Nominating Committee: Mark P. Carthy, John P. Donoghue and Nicholas G. Hatsopoulos

Back to Top